Magnesium aspartate, the chelated magnesium salt of aspartic acid, it is a mineral supplement. Chemical action This form of magnesium supplementation has increased bioavailability compared to magnesium oxide and magnesium citrate. There were some promising clinical trials conducted in the 1960s that found a combination of magnesium and potassium aspartates had a positive effect on fatigue and they reduced muscle hyper-excitability. In its evaluation in 2005, the AFC Panel concluded that in humans the bioavailability of magnesium from magnesium L-aspartate was similar to that from other organic magnesium salts and the more soluble inorganic magnesium salts. Overall, it was concluded that organic salts of magnesium have the greatest water solubility and demonstrate a greater oral absorption and bioavailability compared to less soluble magnesium preparations such as magnesium oxide, magnesium hydroxide, magnesium carbonate and magnesium sulphate. Dosage Adequate Intake (AI) Magnesium-L-aspartate 1230 mg (magnesium 122 mg) up to 3 times/day Dosage adjustment in renal impairment: Patients with severe kidney failure should not receive magnesium due to toxicity from accumulation. Magnesium supplements and other magnesium containing products, such as antacids, can bind with prescription medicines, reducing their effectiveness. Safety When considering aspartate sources individually, the levels of exposure estimated in this opinion amount up to 6 g/day for calcium aspartate (equivalent to 100 mg/kg bw/day for a 60 kg individual), 5.8 g/day for magnesium aspartate (equivalent to 97 mg/kg bw/day), 4 g/day for potassium aspartate (equivalent to 67 mg/kg bw/day), 0.05 g/day for zinc aspartate (0.8 mg/kg bw/day) and 0.008 g/day for copper aspartate (0.1 mg/kg bw/day). These values are all below those reported to induce amino acid imbalance in intervention trials (6.3 g aspartate/day) and they are, respectively, 7, 7.2, 10.5, 875 and 7000 times lower than the NOAEL for aspartate identified from a 90-day rat study. Based on these margins of safety, the Panel concludes that the use of zinc and copper aspartate, as sources of zinc and copper at the proposed use levels, are not of safety concern but that the use of calcium, magnesium and potassium aspartate could be of safety concern because the margins of safety are considered too low. The Panel notes that if all sources would be used simultaneously, combined exposure will be 16 g/day (equivalent to 267 mg/kg bw/day), which is above the reported amounts inducing amino acid imbalance in intervention trials (6.3 g/day). Furthermore, this value is only 3 times lower than the